Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × NSCLC × Clear all

Phase

Phase 2 51 Phase NA 12 Phase 2/3 6 Phase 4 5 Phase 3 5 Phase 1 3 Phase EARLY_PHASE1 2 Phase 1/2 1

Status

Sponsor Class

INDUSTRY 10 OTHER_GOV 1 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 318 Leukemia, Myeloid, Acute 264 Multiple Myeloma 225 Carcinoma, Non-Small-Cell Lung 220 Prostatic Neoplasms 202 Neoplasms 196 Lymphoma 191 Colorectal Neoplasms 182 Melanoma 177 Leukemia 170 Recurrence 159 Precursor Cell Lymphoblastic Leukemia-Lymphoma 159 Pancreatic Neoplasms 159 Lung Neoplasms 150 Glioblastoma 134 Neoplasm Metastasis 131 Lymphoma, Non-Hodgkin 128 Ovarian Neoplasms 123 Leukemia, Lymphocytic, Chronic, B-Cell 120 Myelodysplastic Syndromes 117 Lymphoma, Large B-Cell, Diffuse 109 Lymphoma, Mantle-Cell 107 Carcinoma, Hepatocellular 102 Lymphoma, Follicular 99 Stomach Neoplasms 96 Carcinoma, Renal Cell 89 Hodgkin Disease 88 Brain Neoplasms 88 Sarcoma 84 Squamous Cell Carcinoma of Head and Neck 72

Interventions

nimotuzumab 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡